aRigen strikes first deal for novel anti-MRSA agent
This article was originally published in Scrip
Executive Summary
Green Cross Corp has acquired rights in South Korea to aRigen Pharmaceuticals' lotilibcin (WAP-8294A2), in what is the first licensing deal for the novel anti-MRSA agent.